Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ektericid is a topical antiseptic solution developed and manufactured by Biolik Biopharmaceutical in Ukraine. It is derived from the oxidation of fish oil, resulting in a mixture of water-soluble products including peroxides and aldehydes. The drug exhibits broad-spectrum antimicrobial activity against pyogenic microflora, such as *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus*, and *Staphylococci*, including antibiotic-resistant strains. It is primarily indicated for the treatment of infected postoperative and traumatic wounds, burns, trophic ulcers, boils, and fistulous forms of osteomyelitis. It is applied topically in undiluted form and is noted for its ability to promote healing in chronic or complicated suppurative processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ektericid.